Latest GREAT POINT PARTNERS LLC Stock Portfolio
$435Million– No. of Holdings #39
GREAT POINT PARTNERS LLC Performance:
2026 Q1: 10.74%YTD: 10.74%2025: 43.33%
Performance for 2026 Q1 is 10.74%, and YTD is 10.74%, and 2025 is 43.33%.
About GREAT POINT PARTNERS LLC and 13F Hedge Fund Stock Holdings
GREAT POINT PARTNERS LLC is a hedge fund based in Greenwich, CT. On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, GREAT POINT PARTNERS LLC reported an equity portfolio of $435.1 Millions as of 31 Mar, 2026.
The top stock holdings of GREAT POINT PARTNERS LLC are , VOR, . The fund has invested 7.2% of it's portfolio in APOGEE THERAPEUTICS INC and 7.2% of portfolio in VOR BIOPHARMA INC.
The fund managers got completely rid off DISC MEDICINE INC, RAPT THERAPEUTICS INC (RAPT) and SOLENO THERAPEUTICS INC (SLNO) stocks. They significantly reduced their stock positions in CULLINAN THERAPEUTICS INC (CGEM), CONTEXT THERAPEUTICS INC (CNTX) and IMMUNOVANT INC (IMVT). GREAT POINT PARTNERS LLC opened new stock positions in SOL-GEL TECHNOLOGIES LTD (SLGL), ALUMIS INC and BRIGHT MINDS BIOSCIENCES INC (DRUG). The fund showed a lot of confidence in some stocks as they added substantially to NEKTAR THERAPEUTICS (NKTR), NEUROGENE INC and CLIMB BIO INC (ELYM).
The top stock holdings of GREAT POINT PARTNERS LLC are , VOR, . The fund has invested 7.2% of it's portfolio in APOGEE THERAPEUTICS INC and 7.2% of portfolio in VOR BIOPHARMA INC.
The fund managers got completely rid off DISC MEDICINE INC, RAPT THERAPEUTICS INC (RAPT) and SOLENO THERAPEUTICS INC (SLNO) stocks. They significantly reduced their stock positions in CULLINAN THERAPEUTICS INC (CGEM), CONTEXT THERAPEUTICS INC (CNTX) and IMMUNOVANT INC (IMVT). GREAT POINT PARTNERS LLC opened new stock positions in SOL-GEL TECHNOLOGIES LTD (SLGL), ALUMIS INC and BRIGHT MINDS BIOSCIENCES INC (DRUG). The fund showed a lot of confidence in some stocks as they added substantially to NEKTAR THERAPEUTICS (NKTR), NEUROGENE INC and CLIMB BIO INC (ELYM).
GREAT POINT PARTNERS LLC Equity Portfolio Value
Last Reported on: 15 May, 2026
GREAT POINT PARTNERS LLC Annual Return Estimates Vs S&P 500
Our best estimate is that GREAT POINT PARTNERS LLC made a return of 10.74% in the last quarter. In trailing 12 months, it's portfolio return was 91.08%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| sol-gel technologies ltd | 21,735,000 |
| alumis inc | 18,859,000 |
| bright minds biosciences inc | 16,053,400 |
| annexon inc | 13,850,000 |
| zenas biopharma inc | 10,245,500 |
| moonlake immunotherapeutics | 9,320,000 |
| vera therapeutics inc | 8,019,770 |
| lb pharmaceuticals inc | 7,398,000 |
New stocks bought by GREAT POINT PARTNERS LLC
Additions
| Ticker | % Inc. |
|---|---|
| nektar therapeutics | 50.17 |
| neurogene inc | 42.86 |
| climb bio inc | 36.2 |
| vor biopharma inc | 27.73 |
| silence therapeutics plc | 26.29 |
| jade biosciences inc | 19.62 |
| zura bio ltd | 10.48 |
| contineum therapeutics inc | 0.02 |
Additions to existing portfolio by GREAT POINT PARTNERS LLC
Reductions
| Ticker | % Reduced |
|---|---|
| cullinan therapeutics inc | -52.68 |
| context therapeutics inc | -52.21 |
| immunovant inc | -27.25 |
| kalvista pharmaceuticals inc | -1.55 |
GREAT POINT PARTNERS LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| fulcrum therapeutics inc | -9,048,000 |
| sana biotechnology inc | -2,849,000 |
| rapt therapeutics inc | -19,684,800 |
| soleno therapeutics inc | -18,520,000 |
| dianthus therapeutics inc | -14,423,500 |
| ultragenyx pharmaceutical in | -6,900,000 |
| upstream bio inc | -8,145,000 |
| disc medicine inc | -19,852,500 |
GREAT POINT PARTNERS LLC got rid off the above stocks
Sector Distribution
GREAT POINT PARTNERS LLC has about 54.9% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 54.9 |
| Others | 45.1 |
Market Cap. Distribution
GREAT POINT PARTNERS LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- SMALL-CAP
- MICRO-CAP
- MID-CAP
- NANO-CAP
| Category | % |
|---|---|
| UNALLOCATED | 45.1 |
| SMALL-CAP | 27.4 |
| MICRO-CAP | 18.9 |
| MID-CAP | 5.7 |
| NANO-CAP | 2.9 |
Stocks belong to which Index?
About 32.7% of the stocks held by GREAT POINT PARTNERS LLC either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 67.3 |
| RUSSELL 2000 | 32.7 |
GREAT POINT PARTNERS LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of GREAT POINT PARTNERS LLC
GREAT POINT PARTNERS LLC has 39 stocks in it's portfolio. About 50.3% of the portfolio is in top 10 stocks. AVTE proved to be the most loss making stock for the portfolio. NKTR was the most profitable stock for GREAT POINT PARTNERS LLC last quarter.
Last Reported on: 15 May, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ALKS | alkermes plc | 0.41 | 50,000 | 1,768,000 | new | |||
| AMLX | amylyx pharmaceuticals inc | 5.59 | 1,750,000 | 24,325,000 | unchanged | 0.00 | ||
| ANNX | annexon inc | 3.18 | 2,500,000 | 13,850,000 | new | |||
| AVTE | jade biosciences inc | 3.11 | 964,462 | 13,550,700 | added | 19.62 | ||
| AVTX | avalo therapeutics inc | 0.43 | 124,666 | 1,861,260 | unchanged | 0.00 | ||
| CGEM | cullinan therapeutics inc | 0.98 | 300,000 | 4,263,000 | reduced | -52.68 | ||
| CMPX | compass therapeutics inc | 1.64 | 1,350,000 | 7,141,500 | new | |||
| CNTX | context therapeutics inc | 1.35 | 2,238,500 | 5,864,860 | reduced | -52.21 | ||
| DRUG | bright minds biosciences inc | 3.69 | 220,000 | 16,053,400 | new | |||
| ELYM | climb bio inc | 2.10 | 1,334,130 | 9,138,790 | added | 36.2 | ||
| FULC | fulcrum therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| HUMA | humacyte inc | 0.52 | 3,750,000 | 2,275,120 | new | |||
| IMMX | immix biopharma inc | 0.73 | 350,000 | 3,188,500 | new | |||
| IMVT | immunovant inc | 3.12 | 545,625 | 13,553,300 | reduced | -27.25 | ||
| KALV | kalvista pharmaceuticals inc | 3.12 | 675,000 | 13,587,800 | reduced | -1.55 | ||
| MLTX | moonlake immunotherapeutics | 2.14 | 500,000 | 9,320,000 | new | |||
| NKTR | nektar therapeutics | 5.23 | 316,453 | 22,768,800 | added | 50.17 | ||
| OCUP | opus genetics inc | 0.34 | 324,340 | 1,475,750 | new | |||
| PALI | palisade bio inc | 1.37 | 3,405,760 | 5,960,080 | new | |||
| PHVS | pharvaris n v | 0.54 | 82,800 | 2,339,100 | unchanged | 0.00 | ||